# A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

> **NCT00531934** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 147 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Doxycline
- **DRUG:** erlotinib [Tarceva]

## Key facts

- **NCT ID:** NCT00531934
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2015-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531934, "A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00531934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*